Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo UPLIZNA Shown to De...
Novartis announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective e...
Roche announced that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OC...
Sterilizable, weldable, sealable thermoplastic elastomer tubing intended for biopharmaceutical processing applications that require low temperature...
Massive Health Workforce Shake-Up: 10,000 Federal Health Agency Employees Face Layoffs Amid Budget Axes Trump administration has begun...
DDL, a leading provider of package, product, and material testing services, is pleased to announce the opening of a new Good Manufacturing Practice (GMP) l...
TARRYTOWN -- Regeneron Pharmaceuticals, and Sanofi announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan ...
Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a...
AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Un...
Akeso Inc. (9926.HK), a leading biopharmaceutical company, has announced major advancements in its antibody drug pipeline, underscoring a transformative ...
Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the trea...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the inve...
The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary pr...
CStone Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submission of a Type II variati...
© 2025 Biopharma Boardroom. All Rights Reserved.
